Search

William Harvey – Not All Heart!

In this series of articles I am going to show you some of the exhibits contained in the Museum of Urology, hosted on the BAUS website (www.baus.org.uk). I expect you will have heard of William Harvey (1578-1657) the 17th Century...

COVID-19: the impact on urology so far

“How very little can be done under the spirit of fear.” Florence Nightingale Since 31 December 2019 when a cluster of pneumonia cases with an unknown cause were first referred to the WHO Country Office in China, there has been...

GentleCath™ intermittent catheters

We know that Urinary Tract Infections (UTIs) are the biggest issue for catheter users. In the United Kingdom, 14 million people suffer from continence problems1. Although hydrophilic coated catheters (2nd generation) brought benefits compared to uncoated catheters (1st generation), users...

International urology returns to Scotland

Founded in 1907, the SIU has established itself as the premier international professional society for urologists. As global interdependence increases, so does the relevance of the Society’s mission to enable urologists in all nations to apply the highest standards of...

Urolink: past, present, future

The mission of Urolink, a sub-committee of the British Association of Urological Surgeons (BAUS) since 1996, has been: “To promote and encourage the provision of appropriate urological expertise and education worldwide, with particular emphasis on the materially disadvantaged.” The importance...

Mesh in urological surgery in the UK – background, reviews and current status

All UK urologists, unless they have been on a 10-year silent retreat, are by now aware of the controversy surrounding surgical use of mesh in general and urological / urogynaecological use of mesh for the surgical treatment of stress urinary...

Trials offering cytoreductive surgery for men with de novo synchronous metastatic prostate cancer

Life expectancy in men diagnosed with de novo synchronous metastatic hormone-sensitive prostate cancer (mHSPC) has risen to a median of 4.8 years with upfront systemic agents (such as docetaxel) in addition to standard androgen deprivation therapy (ADT) [1-3]. Within this...

Endoscopic management of upper tract urothelial carcinoma

Upper tract urothelial carcinoma (UTUC) is a rare disease accounting for 5-10% of all urothelial carcinomas and has an annual incidence in Western countries of 1-2 per 100,000 [1,2]. It occurs more commonly in the pelvicalyceal system as opposed to...

Recent developments in bladder cancer – NMIBC

Every year, roughly 10,300 individuals are diagnosed with bladder cancer in the UK, making it the 11th most common cancer in the UK, and the eighth most common cancer in men [1]. Of those diagnosed with the disease, 75-85% will...